BACKGROUND: The aim of this study was to examine adolescent patients' perspectives on their understanding and decision making about a pediatric phase I cancer study. PROCEDURE: Participants included adolescents ages 14-21 years with cancer (N = 20), all of whom attended a phase I study consent conference. Participants responded to closed- and open-ended questions on a verbally administered structured interview, which assessed aspects of understanding and decision making about the phase I study. RESULTS: All participants decided to enroll in the phase I study. The majority of participants understood that participation was voluntary, entailed risks, and that they could withdraw. Most also believed that participation in the phase I study would increase the length of their lives. The most frequent reasons for enrolling were positive clinical benefit, needing an option, impact on quality of life, and few side effects or fewer than those of current or past treatments. Eighty-five percent of participants reported that they themselves made the final decision about enrollment in the phase I study. CONCLUSIONS: Most participants hoped or expected that the phase I study would provide a direct benefit (increased survival time or cure) and reported that they themselves were the final decision-maker about enrollment. Clinicians may underestimate the role of adolescents, especially if they believe that parents typically make such decisions. Future research should assess the actual participation of children and adolescents during the informed consent process and explore the role of hope in their decision making about phase I studies.
BACKGROUND: The aim of this study was to examine adolescent patients' perspectives on their understanding and decision making about a pediatric phase I cancer study. PROCEDURE: Participants included adolescents ages 14-21 years with cancer (N = 20), all of whom attended a phase I study consent conference. Participants responded to closed- and open-ended questions on a verbally administered structured interview, which assessed aspects of understanding and decision making about the phase I study. RESULTS: All participants decided to enroll in the phase I study. The majority of participants understood that participation was voluntary, entailed risks, and that they could withdraw. Most also believed that participation in the phase I study would increase the length of their lives. The most frequent reasons for enrolling were positive clinical benefit, needing an option, impact on quality of life, and few side effects or fewer than those of current or past treatments. Eighty-five percent of participants reported that they themselves made the final decision about enrollment in the phase I study. CONCLUSIONS: Most participants hoped or expected that the phase I study would provide a direct benefit (increased survival time or cure) and reported that they themselves were the final decision-maker about enrollment. Clinicians may underestimate the role of adolescents, especially if they believe that parents typically make such decisions. Future research should assess the actual participation of children and adolescents during the informed consent process and explore the role of hope in their decision making about phase I studies.
Authors: Kevin P Weinfurt; Liana D Castel; Yun Li; Daniel P Sulmasy; Andrew M Balshem; Al B Benson; Caroline B Burnett; Darrell J Gaskin; John L Marshall; Elyse F Slater; Kevin A Schulman; Neal J Meropol Journal: Cancer Date: 2003-07-01 Impact factor: 6.860
Authors: Melissa K Cousino; Stephen J Zyzanski; Amy D Yamokoski; Rebecca A Hazen; Justin N Baker; Robert B Noll; Susan R Rheingold; J Russell Geyer; Stewart C Alexander; Dennis Drotar; Eric D Kodish Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: H A Tejeda; S B Green; E L Trimble; L Ford; J L High; R S Ungerleider; M A Friedman; O W Brawley Journal: J Natl Cancer Inst Date: 1996-06-19 Impact factor: 13.506
Authors: Liza-Marie Johnson; Angela C Leek; Dennis Drotar; Robert B Noll; Susan R Rheingold; Eric D Kodish; Justin N Baker Journal: Cancer Date: 2015-04-14 Impact factor: 6.860
Authors: Irma M Hein; Pieter W Troost; Martine C de Vries; Catherijne A J Knibbe; Johannes B van Goudoever; Ramón J L Lindauer Journal: Pediatr Res Date: 2015-04-09 Impact factor: 3.756
Authors: Lori Wiener; Adrienne Viola; Benjamin S Wilfond; David Wendler; Christine Grady Journal: J Empir Res Hum Res Ethics Date: 2014-12-17 Impact factor: 1.742
Authors: Victoria A Miller; Justin N Baker; Angela C Leek; Dennis Drotar; Eric Kodish Journal: J Pediatr Hematol Oncol Date: 2014-11 Impact factor: 1.289
Authors: Bryce B Reeve; Molly McFatrich; Jennifer W Mack; Scott H Maurer; Shana S Jacobs; David R Freyer; Janice S Withycombe; Justin N Baker; Sharon M Castellino; Li Lin; Nicole R Lucas; Pamela S Hinds Journal: J Natl Cancer Inst Date: 2020-11-01 Impact factor: 13.506